Search
Entrada Therapeutics Inc
TRDAAdd to Watchlist
6.220USD
-0.280-4.31%
Close 09-24 16:00（ET）
241.46MMarket Cap
LossP/E TTM
About Entrada Therapeutics Inc Company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics Inc Profile
Ticker SymbolTRDA
Company nameEntrada Therapeutics Inc
IPO dateOct 29, 2021
CEODoshi (Dipal)
Number of employees183
Security typeOrdinary Share
Fiscal year-endOct 29
AddressOne Design Center Place
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone18573051825
Websitehttps://www.entradatx.com/
Ticker SymbolTRDA
IPO dateOct 29, 2021
CEODoshi (Dipal)
Company Executives of Entrada Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
36.05K
-7.01%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
36.05K
-7.01%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
36.05K
-7.01%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
13.40K
-12.93%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
FAQs
Who are the top five shareholders of Entrada Therapeutics Inc?
The top five shareholders of Entrada Therapeutics Inc are: Dr. Peter S. Kim, Ph.D.
How many institutions hold shares of Entrada Therapeutics Inc (TRDA)?
As of 2026Q1, 267 institutions hold shares of Entrada Therapeutics Inc, with a combined market value of approximately 31.31M, accounting for 80.65% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1502811.00.